Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque-Reference-Cited by-同舟云学术

Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque

Published:2023-08 Issue: Volume:378 Page:117180
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Marfella Raffaele,Prattichizzo Francesco^ORCID,Sardu Celestino^ORCID,Paolisso Pasquale,D'Onofrio Nunzia^ORCID,Scisciola Lucia,La Grotta Rosalba^ORCID,Frigé Chiara^ORCID,Ferraraccio Franca^ORCID,Panarese Iacopo^ORCID,Fanelli Mara,Modugno Piero,Calafiore Antonio Maria,Melchionna Mario,Sasso Ferdinando Carlo^ORCID,Furbatto Fulvio,D'Andrea Davide,Siniscalchi Mario,Mauro Ciro,Cesaro Arturo,Calabrò Paolo,Santulli Gaetano,Balestrieri Maria Luisa,Barbato Emanuele,Ceriello Antonio,Paolisso Giuseppe^ORCID

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference48 articles.

1. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis;Urban;J. Am. Coll. Cardiol.,2013

2. Pcsk9 inhibitors: clinical evidence and implementation;Sabatine;Nat. Rev. Cardiol.,2019

3. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;N. Engl. J. Med.,2017

4. Cardiovascular efficacy and safety of bococizumab in high-risk patients;Ridker;N. Engl. J. Med.,2017

5. Alirocumab and cardiovascular outcomes after acute coronary syndrome;Schwartz;N. Engl. J. Med.,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study;The Korean Journal of Internal Medicine;2024-09-01

2. Atherogenic lipid profile in patients with statin treatment after acute coronary syndrome: a real-world analysis from Chinese cardiovascular association database;Lipids in Health and Disease;2024-08-28

3. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients Following Acute Coronary Syndromes: From Lipid Lowering and Plaque Stabilization to Improved Outcomes;Journal of Clinical Medicine;2024-08-25

4. PCSK9 and Coronary Artery Plaque—New Opportunity or Red Herring?;Current Atherosclerosis Reports;2024-08-16

5. The role of proprotein convertase subtilisin/kexin 9 (PCSK9) in macrophage activation: a focus on its LDL receptor-independent mechanisms;Frontiers in Cardiovascular Medicine;2024-08-01